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R-RasMammalian proteins that contain an aspartate-histidine-histidine-cysteine-(DHHC) motif have been
recently identiﬁed as a group of membrane-associated palmitoyl acyltransferases (PATs). Among the
several protein substrates known to become palmitoylated by DHHC PATs are small GTPases prenylated at
their carboxy-terminal end, such as H-Ras or N-Ras, eNOS, kinases myristoylated at their N-terminal end,
such as Lck, and many transmembrane proteins and channels. We have focused our studies on the product of
the human gene DHHC19, a putative palmitoyl transferase that, interestingly, displays a conserved CaaX box
at its carboxy-terminal end. We show herein that the amino acid sequence present at the carboxy-terminus
of DHHC19 is able to exclude a green ﬂuorescent protein (GFP) reporter from the nucleus and direct it
towards perinuclear regions. Transfection of full-length DHHC19 in COS7 cells reveals a perinuclear
distribution, in analogy to other palmitoyl transferases, with a strong colocalization with the trans-Golgi
markers Gal-T and TGN38. We have tested several small GTPases that are known to be palmitoylated as
possible substrates of DHHC19. Although DHHC19 failed to increase the palmitoylation of H-Ras, N-Ras, K-
Ras4A, RhoB or Rap2 it increased the palmitoylation of R-Ras approximately two-fold. The increased
palmitoylation of R-Ras cotransfected with DHHC19 is accompanied by an augmented association with
membranes as well as with rafts/caveolae. Finally, using both wild-type and an activated GTP bound form of
R-Ras (G38V), we also show that the increased palmitoylation of R-Ras due to DHHC19 coexpression is
accompanied by an enhanced viability of the transfected cells.almitoyl acyltransferase; GFP,
hromatography; MTT, 3-(4,5-
y Biología Molecular, Facultad
Universitaria, 28040, Madrid,
respo).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Among post-translational modiﬁcation events, protein palmitoy-
lation is emerging as an extremely important and abundant
modiﬁcation of polypeptides being responsible for changes in the
trafﬁcking, activity and localization of the lipidated proteins. The
identiﬁcation of enzymes responsible for this covalent attachment of a
16:0 fatty acid has been elusive for many years. However, using
forward genetic screens in yeast, the laboratories of R. Deschenes and
M. Linder demonstrated that two S. cerevisiae proteins, Erf2/Erf4 are
responsible for the palmitoylation of yeast Ras2 [1,2]. Sequence
analysis revealed that Erf2 is very likely an integral membrane protein
with 4 to 6 transmembrane domains and a hydrophilic domain
containing a so-called DHHC (Asp-His-His-Cys) motive. The DHHC
domain of Erf2 is necessary for the palmitoyl transferase activity, an
observation that lead to the initial assumption that proteins contain-
ing this DHHC motif might be palmitoyl transferases in general.Inspection of sequence databases allowed these authors to conclude
that this motif can be found not only in yeast, but also in C. elegans, D.
melanogaster and mammals, comprising 23 genes containing DHHC
motifs in the human genome.
In the past few years, several palmitoylated cellular proteins have
been shown to be substrates for certain palmitoyl transferases of the
DHHC family. Using cotransfection experiments of a putative substrate
together with each of the 23 mammalian DHHC palmitoyl transferases,
PSD-95 was reported to increase its palmitoylation when cotransfected
with DHHC2, -3, -6, -7, -8, -10, -12, -15, -20 and -21 [3]. In partial
contradiction to this report, recombinantly expressed and puriﬁed PSD-
95 was reported to become efﬁciently palmitoylated when incubated
withpuriﬁedDHHC17 (also calledHIP14) [4]. The fact that overexpressed
DHHC17 displayed no effect on the in vivo palmitoylation of transfected
PSD-95 clearly seems to indicate that the subcellular localization of the
various palmitoyl transferases might determine which substrates are
used in vivo. Using the same approach of overexpression of the
palmitoylatable protein substrate together with each of the 23 DHHC
clones allowed the identiﬁcation of DHHC2, -3, -7, -8 and -21 as palmitoyl
transferases of eNOS [5], DHHC3, -7, -15 and -17 for cysteine string
protein [6] and DHHC3 and -7 for Gαq, GαS and Gαi2 [7].
Othermammalian proteins reported to be palmitoylated bymembers
of the DHHC family of proteins include the gamma2 subunit of the GABA
receptor by DHHC3/GODZ [8], CKAP4/p63 [9] and tetraspanins CD9 and
CD151 by DHHC2 [10].
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themselves beyond the palmitate attachment during the catalytic
cycle have not been reported yet. Sequence inspection of the various
mammalian DHHC PATs allowed us to observe that the human
isoform DHHC19 displays a CaaX box motif located at the carboxy-
terminal end. With that in mind, we have undertaken the study of the
catalytic properties of human DHHC19. We show herein that a
synthetic peptide covering the carboxy-terminal sequence of DHHC19
is a substrate for mammalian farnesyl transferase, hence demonstrat-
ing that its CaaX box is indeed functional. This led us to investigate
more carefully which substrates might become palmitoylated by
DHHC19 with special focus on small GTPases of the Ras and Rho
families, since many of them are known to be isoprenylated and
palmitoylated. In fact, the palmitoylation of K-Ras4A [11], R-Ras [12],
RhoB [13], Rap2 [14] and TC10 [15] has been observed previously. We
show evidence in this manuscript that palmitoylation of R-Ras
increases approximately two-fold when this small GTPase is cotrans-
fected with DHHC19, whereas H-Ras, N-Ras, K-Ras4A, RhoB and Rap2
failed to do so. Since overexpression of DHHC19 leads to an increased
palmitoylation of R-Ras accompanied by signiﬁcant changes in its
cellular functions our data implicate the putative palmitoyl transfer-
ase DHHC19 in the functionality of this small GTPase.
2. Materials and methods
2.1. Materials
All buffers and common laboratory reagents were obtained from
Sigma (St. Louis, MO, USA) if not otherwise indicated. Using a campus
facility, we obtained a rabbit polyclonal anti-GFP and anti-5′-
nucleotidase antisera that were used throughout the paper. Mono-
clonal anti-FLAG, anti-β-COP and anti-HA antibodies were from Sigma
(St. Louis, MO, USA). The rabbit polyclonal anti-caveolin1 antibody
was purchased from BD Transduction Laboratories. Secondary anti-
bodies were purchased from Sigma-Aldrich. Peptides for the in vitro
farnesylation assay were synthesized by Thermo Scientiﬁc (Ulm,
Germany). Compactin was from Merck. Fluoroguard was purchased
from BioRad. Molecular Mass markers were from Fermentas.
2.2. DNA constructs
All oligonucleotides were ordered from Sigma. DHHC19wt was a
generous gift fromDr. Yasuyuki Igarashi (HokkaidoUniversity) andwas
cloned into pEGFP-C1 (Clontech) betweenBamHI and EcoRI. Full-length
wild-type EGFP-H-Ras and EGFP-N-Ras were kindly provided by Dr.
Mark R. Philips (NYU School of Medicine). EGFP-R-Ras, EGFP-DHHC9
and EGFP-HA-RhoB were kindly supplied by Dr. Johan Peränen
(University of Helsinki), Dr. Maurine Linder (Washington University,
Missouri) and Dr. Dolores López Sala (CIBMadrid), respectively. DHHC3
(also known as GODZ)was a generous gift fromDr.MasayoshiMishima
(University of Tokyo). Finally, EGFP-SNAP23 and EGFP-SNAP25 were
generously provided by Dr. Luke H. Chamberlain (University of
Edinburgh). All constructs corresponding to the carboxy-terminal end
of H-Ras (amino acids CMSCKCVLS), N-Ras (amino acids CMGLPCVVM),
R-Ras (amino acids RKKGGGCPCVLL), K-Ras4A (amino acids
KTPGCVKIKKCIIM), Rap2a (amino acids DKDDPCCSACNIQ), DHHC19
(amino acids 268–282 and amino acids 258–262 of the human clone)
were made using long complementary overlapping oligonucleotides
that after annealing were ligated between HindIII and BamHI into
pEGFP-C1 (Clontech). Likewise, complementary oligonucleotides cov-
ering the N-terminus of the Lyn kinase (amino acids MGCIKSKGKD)
were designed and, after annealing, the duplexwas ligated into the pre-
cut poly-linker of the pEGFP-N1 vector (Clontech) between NheI and
BamHI. All internal sequence mutants were obtained using the Quick
Change strategy. 3×FLAG constructs were generated by ligation of an
oligo duplex containing the 3×FLAG sequence into EGFP-R-Ras that hadbeen previously digested with NheI and BsrGI to remove the EGFP
sequence. The sequences of all the cloneswere conﬁrmed by automated
DNA sequencing.
2.3. Recombinant expression and puriﬁcation of rat farnesyl transferase
Dr. Kirill Alexandrov (Max Planck Institute of Molecular Physiol-
ogy, Dortmund, Germany) kindly supplied pGATEV-FTaseα-6HisGST
and pET28a-FTaseß for the recombinant expression of the rat farnesyl
transferase heterodimer. In short, E. coli BL21 (DE3) cells were
cotransformed with both plasmids. 2 l of 2X YT medium were
inoculated with 20 ml of an overnight culture in the presence of
0.1 g/l ampicillin and 0.05 g/l kanamycin to maintain both plasmids.
After reaching an OD of 1, protein expression was induced by the
addition of 1 mM IPTG andmaintained for further 20 h at 220 rpm and
30 °C. Subsequently, the cells were harvested by centrifugation in a
F10 rotor (Sorvall, Norwalk, CT, USA) at 5000×g for 30 min and at
4 °C. Cell pellets were frozen and stored at −80 °C. Protein
puriﬁcation was performed in 50 mM Tris pH 7.0, 150 mM NaCl. For
cell disruption a frozen cell pellet was resuspended in the presence of
0.1 g/ml CHAPS, 0.1 g/ml lysozyme and 0.01 g/ml DNAse I during
30 min on ice. After three sonication cycles of 2 min at 50% on ice, the
lysate was clariﬁed by centrifugation for 15 min at 10,000×g and 4 °C,
ﬁltered using a Whatman ﬁlter paper and loaded on a Ni2+-NTA
column (Qiagen) in the presence of 5 mM imidazole and 1 mMMg2+.
After washing with several column volumes of 5 mM imidazole, the
heterodimer was eluted in 200 mM imidazole. Finally, excess
imidazole was removed in three extensive dialysis steps in 50 mM
Tris pH 7.0 for 2 h at 4 °C.
2.4. In vitro farnesylation assay and HPLC
We followed the procedure described by Kalinin [16]. Brieﬂy, 50 mM
HEPES pH 7.2, 5 mM MgCl2, 1 mM DTT, 3 mM Nonidet P40, 18 µM
farnesyl pyrophosphate (if present), 50 nmol puriﬁed rat franesyl
transferase and 16 nmol of the respective peptides were mixed in a
reaction tube in aﬁnal volumeof 500 µl and incubated at 37 °C for 30 min.
Subsequently, the reactionwas stopped on ice and diluted 1:1 with H2O/
0.1% TFA. In order to chromatographically resolve the modiﬁed peptides,
we used a HPLC system (Beckman System Gold) and a Super Pac Pep-S
5 µmC16 reversed phase column (Pharmacia). For each sample twoHPLC
runs were carried out. The samples were loaded on the column in H2O/
0.1% TFA for 5 min. Then, elution was performed in a gradient of 0–70%
acetonitrile during 60min. Chromatographic proﬁles were recorded at
either 214 nm or 280 nm depending on the presence of a tryptophan
residue in the peptide sequence.
2.5. Mass spectrometry
Approximately 50 µl of the reaction mixture was passed several
times through a ZipTip (Milipore) following the manufacturer's
instructions and ﬁnally the peptide solution was collected. Then
1 µl was spotted onto a MALDI target plate and allowed to air-dry at
room temperature. Subsequently, 0.4 µl of a 3 mg/ml of α-cyano-4-
hydroxy-transcinnamic acid matrix (Sigma) in 50% acetonitrile were
added to the dried peptide digest spots and allowed again to air-dry at
room temperature. MALDI-TOF MS analyses were performed in a
4800 Proteomics Analyzer MALDI-TOF/TOF mass spectrometer
(Applied Biosystems, Framingham, MA) at the Genomics and
Proteomics Center, Complutense University of Madrid. This MALDI-
TOF/TOF operated in positive reﬂector mode, with an accelerating
voltage of 20,000 V. Mass spectra were calibrated internally using
known standards. The expected peptides were selected to MS/MS
sequencing analyses using the 4800 Proteomics Analyzer (Applied
Biosystems, Framingham, MA). MS/MS analyses was performed with
CID on (atmospheric gas was used), 1 Kv ion reﬂector mode and
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calibration were optimized for the MS–MS spectra processing. For
protein identiﬁcation, the non-redundant NCBI database (6,640,940
sequences; 2,276,975,120 amino acids) was searched using MASCOT
2.1 (matrixscience.com) through the Global Protein Server v3.6 from
Applied Biosystems.
2.6. Cell culture, transfection and silencing of the DHHC19 gene using
shRNAs
COS7 and NIH3T3 cells were cultivated in Dulbecco's modiﬁed Eagle's
medium supplemented with 10% fetal bovine serum (Cambrex) in a
humidiﬁed atmosphere containing 5% CO2. For the experiments the cells
were seeded in 6-well or 24-well plates and transfected with Escort IV
(Sigma) following the supplier's instructions. One to two micrograms of
DNAwas used for transfection of one well of a 6-well plate. Transfections
in 24-well plates were scaled down accordingly.
Silencingof theDHHC19genewasperformedusingshRNAspurchased
from Sigma-Aldrich. The purchased plasmids are derived from the pLKO
vector. They are referenced to gene NM_144637 zinc ﬁnger, DHHC-type
containing isoform 19. The sequences used are outlined below:
TRCN0000138832 NM_144637.2-301s1c1
CCGGGTTATCACAGGCTCCCTCTTTCTCGAGAAAGAGGGAGCCTGTG
ATAACTTTTTTG
TRCN0000138529 NM_144637.2-314s1c1
CCGGCCCTCTTTGTCCTTACCTTCTCTCGAGAGAAGGTAAGGACAAA
GAGGGTTTTTTG
TRCN0000137344 NM_144637.2-540s1c1
CCGGCAAGTGGGTCAATAACTGCATCTCGAGATGCAGTTATTGACCC
ACTTGTTTTTTG
TRCN0000134852 NM_144637.2-325s1c1
CCGGCTTACCTTCTTCAGTCTTGTTCTCGAGAACAAGACTGAAGAAGG
TAAGTTTTTTG
TRCN0000134807 NM_144637.2-845s1c1
CCGGCCAGCAACTGGTATTTAACAACTCGAGTTGTTAAATACCAGTT
GCTGGTTTTTTG
Transfection of COS7 cells with the silencing plasmids was
performed 36 h before labelling of R-Ras with tritiated palmitic acid.
We used a control consisting of empty pLKO plasmid (also available
from Sigma-Aldrich).
2.7. Coimmunoprecipitation of R-Ras and its active V38 mutant with
DHHC19
COS7 cells were transfected with 3×FLAG-tegged full-length R-Ras
or its constitutively active V38 mutant in the absence or presence of
GFP-tagged wild-type full-length DHHC19. Cells were lysed in RIPA
buffer at 4 °C. The cellular debris was removed after centrifugation at
3000×g in a refrigerated table-top microcentrifuge. The soluble
fraction was incubated with 10 µg of polyclonal rabbit anti-GFP
antiserum overnight at 4 °C and ﬁnally 25 µl of a protein-A (Sigma-
Aldrich) beads suspension was added to the samples. The cell lysates
were centrifuged at 15,000×g in a table-top refrigerated centrifuge
for 10 min and the supernatants were removed. The beads were
washed extensively with RIPA buffer and the amount of R-Ras that
was coimmunprecipitated with GFP-tagged DHHC19 was determined
using anti-FLAG antibodies. An input control is shown that reﬂects the
amount of wild-type or V38 R-Ras in the initial lysates.
2.8. Metabolic labelling with [3H]-palmitic acid
For assessment of [3H]-palmitate incorporation, COS7 cells ∼20 h
post-transfection were pre-incubated with serum free Dulbecco'smodiﬁed Eagle's medium supplemented with delipidized BSA
(10 mg/ml) for 1 h. Subsequently, 250 µCi/ml [3H]-palmitate (ﬁrst
dried, then resuspended in 10 µl DMSO and diluted in an appropriate
amount of medium with 10 mg/ml delipidized BSA) were added and
the cells were incubated for 5 h at 37 °C. Then the cells were
harvested, lysed in RIPA lysis buffer and 3× SDS application buffer
containing DTT at a ﬁnal concentration of 10 mM was added. Finally
the samples were boiled for no more than 2 min (to avoid thioester
bond hydrolysis) and resolved by SDS PAGE. The gels were ﬁxed and
soaked in Amplify reagent (GE Healthcare) for 20 min. Then they
were vacuum-dried and examined by autoradiography. Duplicate gels
were prepared for Western blotting.
2.9. Metabolic labelling with [14C]-mevalonic acid
COS-7 cells were seeded 24 h prior to transfection in 24-well
plates, and transfected using Escort IV transfection reagent. About
24 h post-transfection cells were pre-incubated with 50 μM compac-
tin in DMEM/10% FBS for 3 h. Meanwhile, 25 μCi [14C]-mevalonic acid
lactone (provided in ethanol) was dried, resuspended ﬁrst in 5 μl
DMSO and then in DMEM/10% FBS supplemented with 50 μM
compactin yielding a ﬁnal concentration of 30 μCi/ml. Cells were
incubated for 20 h in the presence of [14C]-mevalonic acid before
processing for SDS PAGE, Western blotting and autoradiography as
described for metabolic labelling with [3H]-palmitic acid.
2.10. Sample preparation for gel electrophoresis
Generally, samples were prepared in 3× SDS sample buffer
supplemented with a ﬁnal concentration of 5% β-mercaptoethanol
and boiled for 5 min at 95 °C (except for samples from metabolic
labelling experiments). In the case of DHHC19 it was necessary to
avoid boiling the samples for immunodetection in Western blotting.
Therefore, samples for immunodetection of DHHC proteins were incu-
bated at 37 °C for 30 min prior to electrophoresis. Immunoblots were
developed using ECL and a LAS3000 Imaging system from Fuji.
2.11. Enrichment of low-density membrane fractions
Lowdensity caveolin/lipid raft containing fractionswere enriched in
a discontinuous sucrose gradient essentially as described previously,
following our modiﬁcations to Lisanti's original reference [17,18].
Brieﬂy, an appropriate amount of transiently transfected COS7 cells
(typically four F-75 ﬂasks) was lysed in MES buffered saline (MBS)
(25 mMMES pH6.5, 0.15 MNaCl) by 30 0.5×16 mmsyringe strokes on
ice. Subsequently, 1% Triton X-100 (ﬁnal concentration in the lysis
volume)was addedand the sampleswere incubated for 30 min on ice. If
a smaller amount of transfected cells was used, the percentage of Triton
X-100 was scaled down proportionally. After a short centrifugation of
5 min at 1500×g and 4 °C, the supernatants were mixed with an 80%
sucrose solution inMBS and placed in the bottom of the tubes. Then the
rest of the 40–30–5% discontinuous sucrose gradient was formed and
centrifuged for 16 h at 100,000×g and 4 °C in a SW65 rotor (Beckman).
Next day, fractions of 400 µlwere collected from thebottomof the tubes
and precipitated by adding 500 µl ice cold acetone for at least 2 h. The
precipitates were obtained by centrifugation for 10 min at 16, 000×g at
4 °C. The samples were then dried in a Univap for 10 min and prepared
for SDS PAGE by the addition of 75 µl application buffer with 5% β-
mercaptoethanol.
2.12. MTT viability assay
To assess the viability of cells in the presence of R-Ras with or
without cotransfected DHHC19, we quantiﬁed the reduction of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) to its
formazan salt as previously described [19]. Brieﬂy, NIH 3T3 cells were
Fig. 1. Phylogenetic analysis of the carboxy-terminal end ofDHHC19 and subcellular localizationwhen transfected in COS7 cells. (A) The carboxy-terminal sequences ofDHHC19proteinswere
alignedandcompared amongvariousmammals. The accessionnumber for thehuman isoform isAAH22078. The conservedCys residuepresent in theCaaXboxaswell as theﬁnal Ser residue is
markedwith an asterisk. The presence of this Ser residue very likely determines that the protein should become farnesylated rather than geranylgeranylated [38]. (B) Phylogenetic comparison
ofmembers of thehumanDHHC family togetherwith their yeast orthologErf2. Proteins of this familywhichhavebeen reported to increase thepalmitoylationofH-Ras includeDHHC18 [3] and
DHHC9 [20]. All theseDHHCproteins are in the samebranch asDHHC19 (shaded area). The sequence comparison and thephylogenetic analysiswere performedusing theClustalW2program.
(C)Aminoacids 258–282of humanDHHC19were fused in frame toGFPandCOS7cellswere transfectedwith this construct. A clear enrichment inperinuclear areas (left andmiddlepanel) that
display a certain colocalizationwith theGolgimarkerß-COP(labelled in red) canbeobserved.A small fractionof theGFP-taggedDHHC19displaysplasmamembrane localization (middlepanel,
arrows). Cell nuclei are stained with Hoechst and are depicted in blue. (D) Mutant C279S of DHHC19 (amino acids 258–282) fused to GFP displays a clear nuclear and cytosolic staining
characteristic of untaggedGFP(left panel). A similar phenotype canbeobservedwhenCOS7cells transfectedwith thewtversionwere incubatedwith50 µMcompactin for20 h(middlepanel).
The right panel shows the distribution of untagged GFP transfected in COS7 cells for comparison. Bars, 50 µM.
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following day. About 24 h post-transfection the mediumwas changed
to FBS-free DMEM. After another 48 h the medium was removed and
the cells were incubated for ∼4 h in DMEM supplemented with
0.5 mg/ml MTT. Finally, the medium was removed and the precip-
itated salt was dissolved in a 0.04 N HCl/isopropanol solution for
quantiﬁcation at 570 nm.3. Results
3.1. DHHC19 contains a functional CaaX box at its C-terminus
Sequence comparison between the carboxy-terminal end of the
product of the human gene DHHC19 and some of its mammalian
orthologs revealed that the CaaX box is conserved among several
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genes fromhumans, chimps,macaques and smallmammals (cat, shrew,
lemur, etc.) but it is absent from DHHC19 of murine genomes. In
addition, a Cys residue upstream the CaaX box can be observed in most
of the cases, a fact that is indicative of the carboxy-terminus of DHHC19
being probably prenylated and palmitoylated. In addition, phylogenetic
analysis of DHHC genes together with the yeast homolog Erf2 showed
that the DHHC19 gene is evolutionarily related to Erf2, a gene known to
be involved in the palmitoylation of puriﬁed H-Ras and N-Ras in vitro,
two small GTPases that also display CaaX boxes [20] (Fig. 1B).
In order to ascertain if the CaaX box of DHHC19 is functional inside
mammalian cells we decided to fuse the ﬁnal 25 amino acids of this
putative palmitoyl transferase to the GFP reporter. Transfection of
COS7 cells with this construct resulted in a clear perinuclear staining
and a partial membrane labelling (Fig. 1C). The perinuclear distribu-
tion displays a certain colocalization with the Golgi marker ß-COP
(Fig. 1C; red). When we mutated the Cys amino acid present in the
CaaX box and replaced it with a Ser (C279S) the distribution was
clearly altered and the cells displayed a GFP ﬂuorescence that was
indistinguishable from that of the GFP reporter alone (staining of the
cytoplasm and nucleus) (Fig. 1D). Likewise, when the cells were
treated with the statin compactin for 20 h, thereby altering the
normal synthesis of farnesyl pyrophosphate, the ﬂuorescence also
reverted to that of GFP alone. Taken together, our data indicate that
the CaaX box of DHHC19 is functional at least when fused to a GFP
reporter and analyzed in transfected cells.
We next decided to inspect if a synthetic peptide corresponding to
the carboxy-terminal 20 amino acids of human DHHC19 could be a
substrate for recombinant farnesyl transferase. We expressed and
puriﬁed to homogeneity the farnesyl transferase heterodimer
(Fig. 2A) and tested if it could use peptides that display a CaaX box
as substrates. As a positive control we used a peptide corresponding to
the ﬁnal 20 amino acids of H-Ras (Fig. 2B). Additionally, reaction in
the absence of farnesyl pyrophosphate was prepared in parallel as a
negative control. Whenwe analyzed the HPLC elution proﬁle of the H-
Ras peptide at 214 nm in the absence (Fig. 2B, upper panel) or in the
presence (Fig. 2B, bottom panel) of farnesyl pyrophosphate a novel
peak that eluted at 49 min could be observed in the latter (marked
with an asterisk). While the unmodiﬁed peptide eluted at 28 min
approximately (marked with an arrow), the novel peak appeared at
49 min only when farnesyl pyrophosphate was present. This peak was
assigned to the farnesylated form of H-Ras, since it eluted in the more
hydrophobic fractions and its appearance was concomitant with a
decrease in the concentration of the unmodiﬁed peptide. Likewise, we
tested if the carboxy-terminal peptide corresponding to human
DHHC19 could also be a substrate of prenyl transferase. The
unmodiﬁed peptide eluted at 33.5 min approximately and could be
also detected at 280 nm due to the presence of a tryptophan amino
acid in its sequence (Fig. 2C, marked with an arrow). In the presence
of farnesyl pyrophosphate a new peak appeared at 52 min (Fig. 2C,
bottom panel, asterisk). This peak was assigned to the farnesylated
form of the DHHC19 peptide (see below). In addition, we also
analyzed the mixture by mass spectrometry techniques (Fig. 2E). The
MS spectrum displayed the presence of the unmodiﬁed peptide at the
expectedmolecular mass of 1609.90 Dawhereas themodiﬁed peptideFig. 2. The carboxy-termini of both H-Ras and human DHHC19 are substrates for puriﬁed farnesy
were cotransformed inE. coli and after recombinant expression, the heterodimeric farnesyl transfer
by SDS PAGE and Coomassie staining. (B) HPLC analysis of a human H-Ras peptide comprising th
farnesyl pyrophosphate. The reactionwas allowed to proceed for 20 min at 37 °C before injection
acetonitrile gradient (0–70% in 60min) as described in the Section 2 . The arrows indicate the e
prenylated peptide. The elution proﬁle was obtained at 214 nm. (C) Likewise, a peptide corres
recombinant, puriﬁed prenyl transferase. Elution was monitored at 280 nm and the conditions w
assess the isoprenylation ofDHHC19 in vivo, we carried outmetabolic labellingwith its precursor [1
SaaX (DHHC19C279S) orGFP-H-Ras as controls. Thebottompanel is a blotting againstGFP-tagged
is the corresponding autoradiogram. No isoprenoid incorporation could be detected under our as
mammalian prenyl transferase on the DHHC19 peptide and de novo sequencing revealing the prappeared at 1813.97 Da. Thismolecularmass difference of 204 Da is in
agreement with the mass expected with a farnesyl moiety being
attached to the Cys residue within the CaaX box present in the
peptide. MS/MS analysis allowed us to unequivocally identify the
amino acid sequence and the modiﬁed Cys residue, both in the y and
in the b series (Fig. 2E). In addition, we assessed incorporation of the
isoprenemoiety labelling cells with its precursor [14C]-mevalonic acid
in COS-7 cells that overexpress GFP-DHHC19 (Fig. 2D). As a positive
control we used GFP-H-Ras. Amutant version of DHHC19 in which the
reactive cysteine of the CaaX box was mutated to serine (C279S) was
also used. While we managed to detect the incorporation of the
radiolabelled isoprene into H-Ras, labelling of DHHC19 was not
detected. This indicates that detection of DHHC19 is below our
detection limit at the observed expression levels. Unfortunately,
under our assay conditions we were not able to obtain expression
levels of DHHC19 that were comparable to those of H-Ras (Fig. 2D
bottom panel).
3.2. Subcellular distribution of DHHC19
The subcellular distribution of human full-length DHHC19 was
inspected by fusing the gene to the carboxy-terminal end of GFP and
subsequent transfection of the plasmid in COS7 cells. DHHC19
localized predominantly to the perinuclear regions of the cell
(Fig. 3A). When we compared this staining with that of the Golgi
marker ß-COP or with the two different trans-Golgi-network markers
Gal-T and TGN38 we could observe an almost complete overlap in the
latter cases. Hence, DHHC19 localizes predominantly to the trans-
Golgi-network, probably regulating from this site the proper palmi-
toylation of proteins that proceed along intracellular sorting pathways.
Unlike the distribution shown by the ﬁnal 25 amino acids of DHHC19
fused to GFP, no plasma membrane staining could be observed in the
case of the full-length protein. Inspection of the human DHHC19
sequence reveals the existence of four putative transmembrane
helices ﬂanking the ∼50 amino acids DHHC motif, on each side [21].
In order to analyze if the CaaX box positioned at the carboxy-terminus
of DHHC19 dictated a certain subcellular distribution, we mutated
Cys279 and analyzed the phenotype of the full-length C279S DHHC19
mutantwhen fused to the GFP reporter (Fig. 3B). Unlike the phenotype
displayed by the ﬁnal 25-amino acid stretch of DHHC19when fused to
GFP (Fig. 1C and D), mutation of Cys 279 within a full-length context
did not render a signiﬁcant change in the subcellular localizationwhen
compared with the wild-type protein. This led us to conclude that the
subcellular localization is mostly dictated by the transmembrane
helices or by other structural motifs in the global fold of the protein. It
is also conceivable that in vivo the CaaX box of DHHC19 might be
responsible for the preferential localization in membranes with a
certain lipid composition.
With all this in mind we performed sucrose density gradient
centrifugations in order to analyze how the various DHHC19
constructs behaved in terms of association with raft/caveolae
membrane fractions. We used two controls of proteins associated
with detergent-resistant fractions: the GPI-anchored 5′-nucleotid-
ase and caveolin-1 (Fig. 4). These proteins were predominantly
enriched in the fractions 6–8 (1 being the bottom and 10 the top ofl transferase. (A) Plasmids encoding theα and β subunits of mammalian farnesyl transferase
asewas puriﬁedusing aNi2+-NTA afﬁnity resin. Thepurity of the eluted samplewas analyzed
e ﬁnal 15 amino acids incubated in the absence (upper panel) or presence (bottom panel) of
into the HPLC column. Separation was performed using a C16 reversed phase column and an
lution position of the unmodiﬁed peptide, whereas the asterisk denotes the position of the
ponding to the carboxy-terminal 15 amino acids of DHHC19 was tested as a substrate for
ere as stated above. Similar results were obtained in three independent runs. (D) In order to
4C]-mevalonic acid in COS-7 cells overexpressing eitherGFP-DHHC19 or the CaaXboxmutant
H-Ras,GFP-tagged-DHHC19 aswell as its non-prenylatedmutant Cys279Ser. Theupper panel
say conditions. (E) MALDI TOF/TOF fragmentation of the product of the reaction of puriﬁed
esence of the prenylated Cys within the CAAX box. The y and b series are depicted on top.
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associated protein that excludes from rafts/caveolae) and untagged
GFP appear mostly in the bottom fractions, that is, fractions 1–3
(Fig. 4). When we analyzed the ﬂotation behaviour of the chimerascomprising 15 (amino acids 268–282) or 25 (amino acids 258–282)
amino acids of the carboxy-terminus of DHHC19 fused to GFP we
could observe that enriched they reached the low-density fractions
to a limited extent. Likewise, the short DHHC19 chimera with the
Fig. 3. GFP-tagged DHHC19 displays a perinuclear localization. (A) COS7 cells were transfected with a GFP-tagged chimera of full-length DHHC19 and its subcellular distribution was
analyzed by laser confocal microscopy comparing it to three other proteins. The left column shows the distribution of DHHC19, themiddle column the distribution of ß-COP, Gal-T or
TGN38 and the right column is the merge column. Antibodies against ß-COP, a cis-, medium-Golgi marker were added to the permeabilized cells and a Cy3 secondary antibody was
added to reveal its distribution. Alternatively, COS7 cells were cotransfected with the plasmids encoding for the trans-Golgi-network markers Gal-T or TGN38 fused to CFP. Double
positive cells are shown. For clarity, the CFP signal is shown in red. (B) Equally, COS7 cells were transfected with a mutant of full-length DHHC19 in which the Cys residue that
becomes prenylated had been substituted for Ser (C279S) and its colocalization with TGN38 was analyzed by laser confocal microscopy.
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fractions and in this case, no colocalization with caveolin-1-
enriched fractions could be observed. We also cloned as controls
the ﬁnal 11 amino acids of human H-Ras and N-Ras in frame with
GFP and analyzed to which degree they were able to become
enriched in lipid rafts/caveolae. As shown in Fig. 4, these two
constructs appeared in fractions 1–6 and their colocalization with
caveolin-1 was very limited, even considering the fact that N-Ras is
supposed to be prenylated and partially monopalmitoylated and H-
Ras prenylated and partially dipalmitoylated. Consequently, the
rafts/caveolae enrichment of all these short prenylated constructs
seems to be very limited.
Conversely, both full-length wild-type DHHC19 and its non-
prenylated counterpart, both of which presumably have four trans-
membranehelices, localizedpartially to rafts/caveolae (Fig. 4). Thus, this
DHHC isoform seems to be, albeit partially, capable to become enriched
in thedetergent-resistant fractions, in analogy to isoformsDHHC2, -3, -7,
-8 and -21 [5]. Interestingly, the prenylated and dually palmitoylatedfull-length H-Ras displayed a clear partial localization in raft/caveolae,
whereas full-length N-Ras did so to a lesser extent.
3.3. Substrate speciﬁcity of DHHC19
A tempting idea would be that the prenylation of DHHC19 conveys
substrate speciﬁcity for prenylated substrates. Therefore, we started
our search for putative substrates of DHHC19 with H-Ras since its
palmitoylation at Cys amino acids 181 and 184 is well established
[22]. COS7 cells were transfected with GFP-tagged full-length H-Ras
(Fig. 5, left panel) or GFP fused to the ﬁnal 11 amino acids of H-Ras
(that include the prenylation and palmitoylation sites) (Fig. 5, right
panel). Cells were also cotransfected with various DHHC19 constructs
and we inspected the amount of palmitoylated H-Ras that could be
detected by metabolic labelling. When COS7 cells were incubated
with tritiated palmitic acid a clear palmitoylated band could be
observed at the corresponding molecular mass in the absence of any
transfected DHHC19 isoform both for the long and short GFP-tagged
Fig. 4. Full-length DHHC19 is only marginally associated with rafts/caveolae. Sucrose gradient analysis of various constructs transfected in COS7 cells. We used 5′-nucleotidase (a GPI-
anchored protein) and caveolin-1 as markers for rafts/caveolae and their localization was determined using speciﬁc antibodies. Both GFP and the membrane-associated protein ß-COP
appeared in the bottom fractions. In themiddlepanel, short constructs of the carboxy-terminal end ofDHHC19 fused toGFP are shown. Short constructs ofN-Ras andH-Rasunder identical
conditions are shown for comparison. In the bottompanel, theﬂotation pattern ofGFP-tagged full-length constructs of DHHC19, a non-prenylatedmutant C279S,N-Ras andH-Ras are also
depicted. In the two bottom panels GFP-tagged chimeras were used and the localization of the proteins was determined using anti-GFP antibodies. Results are representative of three
independent ﬂotation experiments.
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palmitoyl transferases present in COS7 cells can use H-Ras as a
substrate. Unfortunately, we were unable to observe any increase in
the degree of palmitoylationwhen cells were cotransfectedwithwild-
type DHHC19, a mutant in which the DHHCmotif had been converted
into DHHG, a non-prenylated form of DHHC19 or a non-catalytic
chimera in which the ﬁnal 25 amino acids of DHHC19 had been fused
to GFP (Fig. 5). Consequently, we concluded that DHHC19 does not
display any palmitoyl transferase activity towards H-Ras.
Next, we inspected if overexpression of DHHC19 in COS7 cells could
increase palmitoylation of some cotransfected substrates (Fig. 6A). This
timewe used DHHC9 as a control, since DHHC9 has been reported to beFig. 5. Human H-Ras is not a substrate for DHHC19. COS7 cells were transfected with
GFP-tagged full-length H-Ras (left panel) or the GFP-tagged C-terminal region of H-Ras
(aa 181–189) (right panel). The symbol “—” means that in that well no DHHC plasmid
was cotransfected with H-Ras whereas GFP was transfected in the control lane.
Labelling with [3H]-palmitic acid was performed as described in the Section 2. The gels
were dried and palmitic incorporation was assessed by ﬁlm exposure after 1 week. Cells
were cotransfected with either wild-type DHHC19 or mutants DHHG or SaaX (in which
the CaaX box of DHHC19 CFPS had been converted into SFPS). In addition, COS7 cells
were also cotransfected with a construct in which amino acids 258–282 of DHHC19
(that is, the carboxy-terminal end) had been fused to the GFP reporter. The amount of
GFP-tagged H-Ras loaded was conﬁrmed by Western blot (bottom). Asterisks denote
the position of bands corresponding to the labelled transfected proteins in either case.a palmitoyl transferase for both H-Ras and N-Ras in vitro. When H-Ras,
N-Ras and DHHC9 together with its proposed co-factor GCP16 were
expressed and puriﬁed from a baculovirus system, incubation of the
palmitoyl transferase plus GCP16 with either of the two small GTPases
resulted in increased palmitoylation [20]. However, no studies have
been reported to date in which this result could be corroborated in vivo.
We tested small GTPases with palmitoylatable Cys amino acids that
were located close to theprenylated Cys residue present in the CaaX box
(see sequences in Fig. 6A). In our hands, neither DHHC9 nor DHHC19
were able to result in a clear increased palmitoylation of the small
GTPases H-Ras, N-Ras, RhoB, Rap2 or K-Ras4A (Fig. 6A). Since GCP16 is
ubiquitously expressed, it was not necessary to transfect it as well [21].
Nevertheless, DHHC19 was able to induce a two-fold increase in the
palmitoylation of R-Ras. This increase is similar to that reported for
eNOS in the presence of DHHC21 (three-fold in this case), which is the
palmitoyl transferase that regulates its palmitoylation in the endothe-
lium [5] or for PSD95 in the presence of DHHC2 (2.8-fold) or DHHC3
(2.4-fold) [3]. The position of the transfected DHHC19 and DHHC9
PATs obtained in all these substrate labelling experiments is shown on
the bottom right panel of Fig. 6A.
We are well aware of the fact that the complete ineffectiveness
of DHHC9 as a palmitoyl transferase when confronted with H-Ras and
N-Ras as substrates is somehow in contradiction with previous results
[20]. However, it is possible that the published palmitoylation of H-Ras
and N-Ras by DHHC9 can be observed only in vitro, when the
recombinant puriﬁed proteins are incubated together but not in vivo
inside the cell. This could also be a possible explanation for previous
apparently contradictory data [4].
Since prenylation of a certain protein substrate did not seem to be a
general requirement for substrate recognition by DHHC19, we also
tested three additional protein substrates: the myristoylated and
palmitoylated Lyn kinase, for which no DHHC palmitoyl transferase
has been identiﬁed yet, as well as SNAP25 and SNAP23 for which
Fig. 6. Identiﬁcation of R-Ras as a substrate for DHHC19. (A) Among various palmitoylated small GTPases, R-Ras is the only substrate of DHHC19. COS7 cells were transfectedwith
plasmids encoding for six small GTPases known to be palmitoylated: H-Ras, N-Ras, R-Ras, RhoB, Rap2 and K-Ras4A. All of them were GFP-tagged and the ﬁrst four of them
correspond to full-length proteins. Conversely, Rap2 and K-Ras4A were chimeras of GFP fused to their carboxy-terminal 11 amino acids, which include the palmitoylation sites.
Loading controls are shown at the bottom of each gel. The position of the band corresponding to the palmitoylated transfected protein is marked with an asterisk. Each of the six
substrate proteinswas cotransfectedwith an empty plasmid, with DHHC19 orwith DHHC9. The amino acid sequences corresponding to the carboxy-terminal ends of the six small
GTPases tested are also shown (box). The Cys residue of the CaaX box is in bold whereas the palmitoylatable Cys amino acids are shaded. Representative immunodetection of the
GFP-tagged transfected DHHC19 and DHHC9 palmitoyl transferases in COS7 cells is shown (right panel). (B) In addition, three other non-isoprenylated substrates were tested.
The N-terminal 10 amino acids of the kinase Lynwere fused to the GFP reporter, transfected in COS7 cells and tested in order to inspect if the degree of palmitoylation is increased
in the presence of DHHC19 or DHHC9 (left panel). Likewise, GFP-tagged full-length SNAP23 and SNAP25were also tested in the presence of these two palmitoyl transferases. The
position of the band corresponding to the palmitoylated transfected protein ismarkedwith an asterisk. (C) As a control for our assay conditions, we cotransfected GFP-tagged full-
length SNAP25 with DHHC3 (GODZ), a previously published PAT-substrate pair. Palmitate incorporation increased considerably in the presence of GODZ. Results are
representative of three independent experiments.
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[3,4]. In all three cases, the proteins were fused to the GFP reporter. In
the case of Lyn kinase, just the 11 amino-terminal amino acids were
fused, whereas in the case of SNAP25 and SNAP23, the full-length
proteins were tested. As shown in Fig. 6B, neither DHHC9 nor DHHC19
were able to increase the palmitoylation levels of the product of these
three genes when transfected in COS7 cells. However, cotransfection of
SNAP25withDHHC3 resulted in a very signiﬁcant increase in thedegree
of palmitoylation (over three-fold).
3.4. DHHC19 is a major PAT towards R-Ras
Since R-Ras was the only small GTPase for which DHHC19 dis-
played PAT activity, we focused on the physiological effects that its
hyperpalmitoylation might produce. First, we wanted to make sure
that the effect on R-Ras was not perturbed by the bulky GFP tag. As
shown in Fig. 7A, cotransfection of COS7 cells with DHHC19, but not
with GFP or DHHC9, also increases 3×FLAG-R-Ras palmitoylation
∼1.8-fold. Likewise, the DHHC19 C142G mutant, in which the
catalytic motif is converted into DHHG, failed to increase 3×FLAG-
R-Ras palmitoylation when compared with its wild-type counterpart(Fig. 7B). Next we decided to knock down the endogenous DHHC19
levels present in COS-7 cells using shRNA targeted against this gene.
We used ﬁve different commercially available shRNA speciﬁcally
designed against the DHHC19 gene (NM_144637) and tested the
palmitoylation levels of transfected full-length R-Ras. As shown in
Fig. 7C, all the transfected shRNA were able to diminish, albeit to a
different degree, the palmitoylation of R-Ras in COS-7 cells. In fact,
shRNA529, shRNA344 and shRNA344 lowered R-Ras palmitoylation
levels to approximately 50% of those found in untreated cells. The
fact that some R-Ras palmitoylation remains even in the presence
of the various shRNAs might well indicate that other cellular
DHHC isoforms might be also active towards R-Ras within COS-7
cells.
3.5. Hyperpalmitoylation of R-Ras by DHHC19 modulates its interaction
with membranes
The increased palmitoylation of R-Ras caused by DHHC19 coex-
pression in COS7 cells resulted in a clear shift in the supernatant:pellet
ratio of R-Ras distribution when cell fractionation was performed
(Fig. 8A). GFP-R-Ras transfected in COS7 cells and fractionated at
Fig. 7. Characterization of DHHC19 PAT activity towards R-Ras. (A) Palmitoylation of
3×FLAG-tagged R-Ras also shows moderate, but stable increase in the presence of GFP-
DHHC19 but not in the presence of GFP or GFP-DHHC9 in COS-7 cells. Immunodetection
was carried out with a monoclonal anti-FLAG antibody. The mock lane refers to
untransfected cells. (B) Palmitoylation of 3×FLAG-R-Ras is not increased in the presence
of a DHHG (C142G)mutant of DHHC19 in COS-7 cells. Immunodetectionwas carried out
with a monoclonal anti-FLAG antibody. The “empty plasmid” lane corresponds to cells
transfected with GFP alone. The transfection levels of wild-type DHHC19 and its C142G
mutant were similar. (C) GFP-R-Ras palmitoylation decreases in the presence of ﬁve
shRNAs targeted to the DHHC19 transcript in COS-7 cells by silencing the endogenous
DHHC19 gene product (the shRNA templates were purchased from Sigma-Aldrich and
sequences are commented in materials and methods). Note that palmitoylation is not
completely abrogated, suggesting that redundant R-Ras PATs must exist in COS-7 cells.
Transfection with an empty plasmid (pLKO) does not result in diminished R-Ras
palmitoylation (right panel). Quantiﬁcation of the immunodetection and autoradiog-
raphy bands in all caseswas carried out using the FujiMultiGauge software package. The
numeric values were obtained normalizing the radioactivity signal to the amount of
protein as judged by the ECL signal. In all cases data are representative of at least three
independent experiments.
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fractions. Coexpression with both the wild-type GFP-DHHC19 and the
prenylation defective mutant (C279S) resulted in an increase in the
percentage of membrane-associated R-Ras. Consequently, in terms of
R-Ras palmitoylation, the prenylation motif in DHHC19 seems to be
dispensable for activity. Likewise, the C279S DHHC19 mutant
increased R-Ras palmitoylation to a similar extent as its wild-type
counterpart DHHC19 (data not shown). Finally, a control was
performed with compactin, diminishing the amount of prenylated
R-Ras and increasing the soluble to particulate ratio of transfected R-
Ras. Laser confocal microscopy revealed that YFP-R-Ras localized to
the cellular plasma membrane as well as perinuclear areas of the cell
(Fig. 8B). Cotransfection with CFP-DHHC19 did not signiﬁcantly
disturb the subcellular distribution of R-Ras. This result is consistent
with R-Ras being palmitoylated by DHHC19 in Golgi areas hence
modulating its plasmamembrane-Golgi trafﬁcking cycle, in analogy to
the well-studied case of H-Ras [23].
We also decided to test if the increased palmitoylation of R-Ras
caused by DHHC19 coexpression affected its ability to concentrate in
low-ﬂuidity subdomains of the caveolae/raft type. As shown in
Fig. 8C, transfection of COS7 cells with full-length R-Ras resulted in a
partial localization in fractions in which caveolin-1 was also present.
Cotransfection of DHHC19 with R-Ras resulted in an increased
enrichment of R-Ras in these upper (lower density) fractions, in
agreement with the known localization of prenylated plus palmitoy-
lated H-Ras proteins to these subcellular domains [24,25]. Conse-
quently, DHHC19 is able to promote R-Ras palmitoylation resulting
not only in an increased association with total cellular membranes,
but speciﬁcally with membranes enriched in cholesterol/sphingo-
myelin that are partially resistant to Triton X-100 solubilization.3.6. DHHC19 increases the viability of R-Ras transfected cells
R-Ras is known to increase branching morphogenesis and cell
growth in murine UB cells [26] and its activated form R-Ras-G38V is
known to increase signiﬁcantly DNA synthesis and BrdU incorpora-
tion in Swiss 3T3 cells [27]. We tested if increased palmitoylation of R-
Ras could affect its activity in a MTT viability assay of transfected
NIH3T3 cells (Fig. 8D). As a control we transfected the NIH3T3 cells
with a short R-Ras-GFP chimera that only included the ﬁnal carboxy-
terminal 11 amino acids hence lacking the GTP binding domain. As
expected, wild-type R-Ras displayed a very modest increase in cell
viability, although its increased palmitoylation by DHHC19 resulted in
a clear increased viability. The activated form of R-Ras (V38) also
positively modulated when DHHC19 was cotransfected H-Ras-V12 (a
constitutively active mutant version of H-Ras) was used as a positive
control of the assay and was compared to the short R-Ras version.
Finally, we decided to analyze if R-Ras and DHHC19 could be
partially associatedwithin the cell, assuming that the Golgi-associated
DHHC19 might be using R-Ras as a substrate in perinuclear areas of
the cell where they colocalize (Fig. 8E). When GFP-tagged DHHC19
was cotransfected with 3×FLAG-tagged R-Ras and the cell lysate was
immunoprecipitated with anti-GFP antibodies a modest but repro-
ducible quantity of R-Ras could be found in association with the
palmitoyl transferase (Fig. 8E).
4. Discussion
Protein palmitoylation is a crucial post-translational modiﬁcation
implicated in a large number of cellular processes as diverse as protein
trafﬁcking, protein stability or lateral segregationofmembraneproteins.
Regulatory mechanisms have been elusive for a long time in part due to
the difﬁculties in purifying PAT activity from cells. The breakthrough
was the discovery of a protein family in yeast that displayed PAT activity
[2]. Several other pertaining reports ensued [3,4,20], establishing the
importance of theDHHC family of palmitoyl transferases, comprising 23
isoforms in humans. All themembers of this newprotein family contain
a common cysteine rich domain (CRD) and a conserved aspartate-
histidine-histidine-cysteine-(DHHC)-motif that also seems to be crucial
for PAT activity in most cases [2,3].
In this work we analyzed the isoform DHHC19 of the DHHC family
of PATs, being the onlymember containing a C-terminal CaaX box that
is conserved among various species. This motif is a well established
consensus sequence for protein prenylation, another common post-
translational lipid modiﬁcation. We could unequivocally show the
functionality of the CaaX motif of a short chimera of DHHC19 both in
vitro and in vivo (Figs. 1C and D and 2B and C) although, within our
detection limits, we were unable to detect the incorporation of the
radiolabelled isoprenoid moiety in full-length DHHC19. With this in
mind we set out to explore the functionality of DHHC19 as a PAT.
All DHHC associated PAT activities described so far are not speciﬁc
for a single substrate. In fact, in all reports that relied on in vivo
palmitoylation assays several DHHC family members exhibited redun-
dant PAT activity for any given substrate. There have been attempts to
classify DHHC substrate ﬁdelity in vitro based on the presence of certain
structuralmotifs in the substrates, likemyristoylation, isoprenylation or
proximity of reactive cysteines to transmembrane regions [28], but in
vivo data rather points at a more complex speciﬁcity pattern, likely
depending on the subcellular colocalization of a given PAT and its
substrate.
Many small GTPases that contain a conserved CaaX box are also
palmitoylated at upstream cysteine amino acids. This dual post-
translational modiﬁcation has been described for H-Ras [22], N-Ras
[22], K-Ras4A [11], R-Ras [12], Rap2A [14], TC10 [15], RhoB [13] and
Rac1 [29] among others.
It is conceivable that a PATwith aCaaXboxmight be using substrates
that are similarly modiﬁed at the C-terminal end, if that favours
Fig. 8. DHHC19 overexpression alters the physiological function of R-Ras. (A) COS7 cells were transfected with full-length wild-type GFP-R-Ras in the absence (lanes 1–2) or
presence of wild-type GFP-DHHC19 (lanes 3–4) or the mutant C279S (lanes 5–6) and the lysates were separated into supernatant and particulate fractions. As a control, a sample
was also treated with a statin in order to inhibit prenyl incorporation into R-Ras (lanes 7–8). (B) YFP-R-Ras localizes to the plasmamembrane and perinuclear areas of the cell (upper
panel) whereas coexpression of CFP-DHHC19 and YFP-R-Ras (lower panels) does not signiﬁcantly alter the latter's distribution. (C) COS7 cells were transfected with full-lengthwild-
type GFP-R-Ras in the presence or absence of GFP-DHHC19 and the lysate was processed in a sucrose density gradient as described in the Section 2. The presence of the caveolae/rafts
membrane fractions was identiﬁed using an anti-caveolin-1 antibody. Results are representative of three independent experiments. (D) NIH3T3 cells were transfected with various
constructs and a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) viability assay was performed. Data are expressed as mean of ﬁve independent experiments,
S.D. *, pb0.05. In the case of H-Ras V12 *, pb0.05 referred to the control cells transfected with the short R-Ras construct. (E) The association of R-Ras and DHHC19 was evaluated by a
co-immunoprecipitation assay. COS7 cells were transfected with constructs of a 3×FLAG-tagged wild-type and V38 mutant of R-Ras in the absence or presence of a GFP-tagged
DHHC19 construct. A polyclonal anti-GFP serum was used to immunoprecipitate the GFP-tagged DHHC19 and the presence of bound R-Ras was analyzed using an anti-FLAG
antibody. The “input” corresponds to an immunoblot performed on the total lysates using anti-FLAG antibodies prior to the immunoprecipitation.
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would have been in accordance with the previously reported in vitro
data [28] suggesting the classiﬁcation of substrates by structural
motives. Consequently, we designed a ﬁrst series of experiments,
where we inspected the effect of DHHC19 on H-Ras (Fig. 5) as a
representative example of the family of small GTPases that are post-
translationally prenylated and palmitoylated. In principle throughout
the paper, we followed the procedure proposed by Fukata et al. [30],
where DHHC proteins are co-overexpressed with a putative substrate
and palmitoylation is monitored by metabolic labelling, gel electropho-
resis and autoradiography. Neither H-Ras or N-Ras, nor any other
members of the family of small GTPases that we tested showed
enhanced palmitoylation in the presence of DHHC19 with the notable
exception of R-Ras (Fig. 6). Besides the modest though reproducible
increase in palmitoylation of R-Ras, we could demonstrate that this
effect resulted in a stronger general membrane association as judged
from the enrichment in the particulate fraction (Fig. 8A) and an increase
in the association of R-Raswith lipid raft/caveolae (Fig. 8C), aswell as in
an enhanced viability of cultured cells that had been cotransfectedwith
both proteins (Fig. 8D). It is remarkable that this increment in R-Ras
palmitoylation can have pronounced physiological effects such in the
case of cell viability. This is also consistentwith the ampliﬁcatory role of
signalling circuits,where small changes in signallingmolecules canhave
very profound consequences for cell fate.
In support of our data, other Ras proteins, such as H-Ras and N-Ras
have previously been shown to enhance proliferation [31], tumor
invasiveness and progression in a palmitoylation dependentmanner. In
these experiments, palmitoylation defective mutants of Ras proteins
were unable to bind stably to the plasma membrane, which lead to the
loss of their signalling activity. Our results indicate an increased
signalling capacity of hyperpalmitoylated R-Ras that is accompanied
by a stronger association to the plasma membrane and to lipid rafts/
caveolae. Although the importance of lateral sorting of R-Ras has not
been broadly addressed in the current literature, it has been shown that
a palmitoylation defectivemutant of R-Ras (C213A) was retained in the
Golgi and failed to be properly transported to the plasma membrane,
while wild-type R-Ras has been shown to effectively exit the Golgi and
to be predominantly located in focal adhesions [32]. This effect is
comparable to other Ras proteins, where the lack of palmitoylation
results in Golgi accumulation [33]. Furthermore, R-Ras function has
been shown to be involved in integrin signalling, probably from focal
adhesions, and to involve different signalling routes than the classical
Ras proteins. Taking into account all this evidence, it is feasible that there
exists a speciﬁc PAT for R-Ras that does not interfere with the other Ras
isoforms that activate different signalling routes in the cell.
Finally, we correlate an increased association of R-Raswith lipid rafts/
caveolae-like domainswith an increase in physiological activity, as judged
from enhanced viability of transformed cells. The correlation would be
supported by the fact that N-Ras in its GTP loaded (active) state depended
on cholesterol-sensitivemicro domains for its clustering [25]. R-Ras is also
monopalmitoylated like N-Ras (and unlike dipalmitoylated H-Ras).
Hence, hyperpalmitoylation of R-Ras by DHHC19 could increase its
partition into lipid raft/caveolae-likedomainsandenhance its activity.We
could observe this effect both towards wild-type R-Ras and towards its
constitutively GTP loaded version (R-Ras-G38V). Therefore, hyperpalmi-
toylation seems to affect both R-Ras pools in a similar way.
Interestingly, we were unable to reproduce the previously reported
in vitro data where H-Ras was shown to be palmitoylated by
recombinantly expressed DHHC9 and its co-factor GCP16. GCP16 is
ubiquitously expressed and DHHC9 was shown to be expressed in
several tissues aswell [21]. However, overexpression of DHHC9 in COS7
cells together with GFP-tagged H-Ras did not result in an increased
palmitoylation in our hands. Consequently, in vitro palmitoylation data
might not exactly reﬂect the in vivo situation where the subcellular
localization of DHHC proteins relative to their potential substrates
dictates substrate speciﬁcity.Subcellular localization studies of DHHC19 revealed that it is
mainly located to trans-Golgi regions as judged by the colocalization
with the trans-Golgi markers TGN38 and Gal-T (Fig. 3). Interestingly,
R-Ras like other Ras isoforms also localizes to Golgi regions, while
displaying some plasma membrane localization as well. Rocks et al.
showed that a palmitoylation/depalmitoylation dependent process
redistributes H-Ras between Golgi and plasma membrane [23]. It
would be intriguing if R-Ras localization was controlled by a similar
mechanism, where its palmitoylation depended on DHHC19 in the
Golgi. This possibility, however, has yet to be established.
Northern Blot analysis showed that DHHC19 is speciﬁcally
expressed in lung, testis, thymus and small intestine [21] whereas
R-Ras is expressed in all tissues tested [34]. Therefore, DHHC19might
be responsible for the modulation of R-Ras in tissues in which both
proteins concur while other DHHC proteins might be responsible for
the modulation of R-Ras palmitoylation in other tissues in which
DHHC19 is not expressed. Notably, it has been shown that R-Ras is
speciﬁcally modulated in testis and brain by a Ras-Guanine
Nucleotide releasing factor (Ras-GRF) that is expressed only in
these tissues [34]. It is possible that in the case of DHHC-dependent
palmitoylation the expression patterns of DHHC proteins deﬁne their
cognate substrates and hence their modulation. In this work, R-Ras
palmitoylation was monitored in COS7 cells (green monkey kidney
cells).We could observe endogenous palmitoylation of R-Ras in COS7
cells (just as with other substrates, such as SNAP25 or RhoB for
instance). Considering the results obtained with the DHHC19
shRNAs, we could conclude that these cells must express DHHC19
together with other PATs that can also use R-Ras as a substrate.
Others have reported that DHHC protein speciﬁcity can depend on
inherent protein binding domains like ankyrin repeats, like in the
case of DHHC17 (HIP14) [4,35]. On the other hand, speciﬁcity also
seems to be conferred by the expression pattern in distinct micro
environments of the cell. It will surely be of interest in the future to
address more in detail the question of how the DHHC family of PATs
achieves substrate speciﬁcity in vivo.
Finally, while we could show that DHHC19 contains a putative
prenylation motif at the C-terminal end, it did not seem to be of
importance for DHHC19 mediated R-Ras modulation (Fig. 8A). In fact,
both the wild-type and the mutant with the altered CaaX box equally
promote R-Ras palmitoylation and its increased association with
membranes. Possibly, isoprenylation of DHHC19 is not essential for its
effect on R-Ras in general, but for a more subtle ﬁne tuning of its
activity. With our methodology, we only capture average steady state
palmitoylation and its effects on target proteins. It is conceivable that
isoprenylation of DHHC19 has some effect on the time course of the
palmitoylation of certain substrates. On the other hand, it has been
reported that isoprenylation of the SNARE protein Ykt6 increases its
stability [36]. Furthermore, isoprenylation of H-Ras has previously
been shown to be necessary for the interaction with its co-factors [37]
and not solely for membrane tethering. Hence, isoprenylation can
have diverse functions both in membrane and in soluble proteins that
go beyond a mere membrane anchor. The isoprenylation of DHHC19
could therefore be responsible for the ﬁne tuning of its micro
localization in the cell, for its stability or for the interaction with co-
factors or substrates. As a matter of fact, isoprenylation is not
important for the effects on R-Ras that we addressed, but its
importance might lie in aspects that more detailed studies will
bring to light.
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